1.5.1.33: pteridine reductase
This is an abbreviated version!
For detailed information about pteridine reductase, go to the full flat file.
Word Map on EC 1.5.1.33
-
1.5.1.33
-
leishmania
-
dihydrofolate
-
trypanosoma
-
antileishmanial
-
antifolate
-
promastigotes
-
leishmaniasis
-
trypanosomatids
-
pterins
-
donovani
-
amastigotes
-
trypanosomiasis
-
dhfr-t
-
trypanothione
-
reductase-thymidylate
-
tarentolae
-
dihydrobiopterin
-
glucantime
-
medicine
-
drug development
-
pharmacology
- 1.5.1.33
- leishmania
- dihydrofolate
- trypanosoma
-
antileishmanial
- antifolate
- promastigotes
- leishmaniasis
-
trypanosomatids
- pterins
- donovani
- amastigotes
- trypanosomiasis
-
dhfr-t
- trypanothione
-
reductase-thymidylate
- tarentolae
- dihydrobiopterin
-
glucantime
- medicine
- drug development
- pharmacology
Reaction
Synonyms
Atu1130, EC 1.1.1.253, H region methotrexate resistance protein, LaPTR1, LbPTR1, LdPTR1, LmPTR1, LpPTR1, More, NADPH-dependent short-chain dehydrogenase/reductase pteridine reductase, NADPH-dihydropteridine reductase, PruA, pteridine reductase, pteridine reductase 1, pteridine reductase I, PTR1, reductase, dihydropteridine (reduced nicotinamide adenine dinucleotide phosphate), Tb-PR, TbPTR1, tcptr1
ECTree
Advanced search results
Application
Application on EC 1.5.1.33 - pteridine reductase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
medicine
pharmacology
-
successful antifolate chemotherapy in Leishmania will have to target simultaneously both pterine reductase 1 and dihydrofolate reductase-thymidylate synthase
drug development
-
the enzyme is considered a promising target for anti-leishmanial drug development and several inhibitors that share the substrate scaffold
drug development
the classical antifolates targeting dihydrofolate reductase (DHFR) are ineffective towards trypanosomatid parasites owing to a metabolic bypass by the expression of pteridine reductase 1 (PTR1). The combined inhibition of PTR1 and DHFR activities in Trypanosoma parasites represents a promising strategy for the development of new effective treatments for human African trypanosomiasis (HAT)
enzyme is a target for development of improved therapies for infection by trypanosomatid parasites
medicine
enzyme is an important chemotherapeutic target for drugs against Leishmania